EUCTR2018-003483-32-FR进行中（未招募）1 期
BLINAtumomab after R-CHOP debulking therapy for patients with Richter Transformation. - FILOCLL13-BLINART
FILO0 个研究点目标入组 35 人开始时间: 2019年3月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Confirmed diagnosis of chronic lymphocytic leukemia or small lymphocytic lymphoma according to the revised iwCLL criteria19 with biopsy proven transformation to diffuse large B-cell lymphoma, consistent with RS according to the 2016 WHO classification.
- •Both patients with previously treated or treatment-naïve CLL are eligible
- •Age greater than or equal to 18 years
- •ECOG performans status <3
- •Patients must meet the following hematologic criteria at screening, unless they have significant bone marrow involvement of either CLL or RS cells confirmed on biopsy: absolute neutrophil count =1.0 G/L, platelet count =50 G/L independent of transfusion within 7 days of screening
- •Subject must have adequate coagulation, renal, and hepatic function at screening
- •Adequate left ventricular ejection function (> 50 %)
- •Patients who have undergone prior allogeneic hematopoietic stem-cell transplantation are eligible as long as they do not have significant active graft versus host disease and that their transplant day 0 is > 6 months from their first dose of protocol therapy
- •Female patients of child bearing potential must have negative pregnancy test and use an effective method of birth control during treatment period and 48h thereafter; Males must use an effective method of birth control during treatment period and 48h thereafter.
- •Ability to understand and the willingness to sign a written informed consent document
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 15
排除标准
- •Patients with the Hodgkin variant of RS
- •Patients with previously treated RS
- •History or presence of clinically relevant disorder affecting the central nervous system (CNS)
- •Known active DLBCL in the CNS (confirmed by CSF analysis)
- •Steroids treatment (= 20 mg for one week) before inclusion
- •Allogeneic HSCT within 6 months before inclusion
- •Active graft-versus-host disease
- •History of other malignancies, except: i) malignancy treated with curative intent and with no recurrence over the last 5 years ii) adequately treated non-melanoma skin cancer without evidence of disease iii) adequately treated carcinoma in situ without evidence of disease
- •History of human immunodeficiency virus
- •Hepatitis B or C seropositivity (unless clearly due to vaccination)
- •Pregnant or breastfeeding women
- •Unwilling or unable to participate in all required study evaluations and procedures. Unable to understand the purpose and risks of the study and to provide a signed and dated informed consent form and authorization to use protected health information (in accordance with national and local subject privacy regulations)
- •Abnormal screening laboratory values as defined as following: a) ALT (SGOT) and/or ALT (SGPT) and/or ALP > or =5 x upper limit of normal (ULN); b) Total bilirubin > or = 1.5 x ULN, unless due to Gilbert's disease; c) Creatinine > or = 2.0 x ULN or creatinine clearance <50 mL/min (calculated).
- •Fertile male and female patients who cannot or do not wish to use an effective method of contraception during treatment and for 48h after the final treatment used for the purposes of the study
- •Treatment with other investigational agent or participating to another trial within 30 days prior to entering the study
- •No affiliated to social security
研究者
相似试验
进行中（未招募）
1 期
CombinatiOn of NivolumAb plus Relatlimab in patients with Advanced or metastatic soft-tissue Sarcoma: a proof-of-concept randomized phase II studyAdvanced soft-tissue sarcomaMedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10039494 Term: Sarcoma NOS System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-002332-81-FRInstitut Bergonié67
尚未招募
不适用
Blinatumomab for minimal residual disease before hematopoietic stem cell transplantation in pediatric B-cell precursorKCT0006135Seoul National University Hospital20
进行中（未招募）
1 期
IMMULAB – A phase II trial of immunotherapy with pembrolizumab in combination with local ablation for patients with early stage hepatocellular carcinoma (HCC)early stage hepatocellular carcinoma (HCC)MedDRA version: 20.0Level: PTClassification code 10073071Term: Hepatocellular carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001381-42-DEInstitut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest30
已完成
不适用
Study of dupilumab administration for refractory adulthood asthmabronchial asthmaJPRN-UMIN000038873Sagamihara National Hospital30
招募中
不适用
Palmitoylethanolamide as adjunctive treatment of Autism: A double blind and placebo controlled trialChildhood autism.Childhood autismIRCT201702171556N96Tehran University of Medical Sciences50